Pentixapharm outlines new clinical development strategy
|
EQS-Ad-hoc: Pentixapharm Holding AG / Key word(s): Study
Ad hoc announcement pursuant to Art. 17 MAR / Section 15 WpHG
Pentixapharm outlines new clinical development strategy Clinical pipeline to be refocused on theranostic precision oncology opportunities to enhance value proposition of lead assets The PTF301 diagnostic trial in Marginal Zone Lymphoma (MZL) will be discontinued. New CXCR4 trials in hematologic malignancies and Bladder Cancer in preparation Berlin, Germany, May 27, 2025 – Pentixapharm AG, the operating subsidiary of Pentixapharm Holding AG, a clinical-stage biopharmaceutical company focused on radiopharmaceuticals, today outlined a new clinical development strategy for its CXCR4 therapeutic and diagnostic oncology programs, following a management review led by recently appointed CEO and CMO Dr. Dirk Pleimes and CBO Henner Kollenberg. The management of Pentixapharm strongly believes the new clinical strategy for the CXCR4 programs will increase the value proposition of the CXCR4 targeting assets. The decision was approved by Pentixapharm’s Supervisory Board at a meeting held earlier today. Pentixapharm will refocus its clinical development efforts and resource into a theranostic basket program that will evaluate the efficacy of the Company’s CXCR4-targeted therapeutic approach across various hematological malignancies that overexpress the CXCR4 chemokine receptor. An additional clinical Phase I/II in trial in Bladder Cancer is currently in preparation. Pentixapharm will provide further detail on these new trials in due course. Following implementation of the new clinical development strategy, the Company’s current PTT101 therapeutic trial in the Central Nervous System (CNS) Lymphoma will be integrated into the theranostic basket program. The PTF301 diagnostic trial in Marginal Zone Lymphoma (MZL) will be discontinued due to low patient recruitment. Outside oncology, Pentixapharm continues its commitment to advance [68Ga]Ga-PentixaFor as a first-in-class, non-invasive diagnostic solution for primary aldosteronism (PA) and explores the best route towards realizing the value for the registrational clinical development and commercialization phase. “This strategic decision will help us to contribute significantly to the value of our theranostic CXCR4 pipeline. We are deeply grateful to the patients, investigators, and teams who have supported our clinical progress. This work has provided us with an excellent basis for the review and re-design of our clinical pipeline. The basket trial program is designed to systematically identify indications where our CXCR4 theranostic platform can deliver the greatest clinical benefit and value to patients with hematologic malignancies,” said Dr. Dirk Pleimes, CEO of Pentixapharm. “We are looking forward to presenting the new trials in more detail at upcoming scientific and investor conferences.” “The review of the clinical pipeline will enable us to focus on larger indications with a higher market potential,” added Henner Kollenberg, CBO of Pentixapharm. “While the previous trials delivered supportive data on our compounds and underlined the strengths of our CXCR4 portfolio, the business case for the orphan drug diagnostic and long recruitment times for both programs represented a significant challenge for their future commercialization. We now look forward to progressing with a renewed focus on improving treatment options and outcomes for thousands of patients with aggressive forms of leukemias, myeloma and lymphoma and more broadly in high-value opportunities from the use of radiopharmaceuticals in precision oncology.”
Forward-looking statements This ad hoc announcement contains forward-looking statements that are based on the current expectations, forecasts and assumptions of Pentixapharm Holding AG. Forward-looking statements are inherently subject to risks and uncertainties because they depend on future events and developments that cannot be fully controlled. Therefore, actual results may differ materially from the expectations expressed herein. Pentixapharm Holding AG assumes no obligation to update forward-looking statements or to adapt them to changes in circumstances, unless required by law.
About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing first-in-class radiopharmaceuticals with strong differentiation and commercialization potential across high-need diagnostic and therapeutic areas. Its pipeline comprises CXCR4-targeted peptides in clinical development and a portfolio of early-stage radionuclide-antibody conjugates, aimed at using precision oncology to treat hematologic malignancies and solid tumors.
For more information, please contact: Pentixapharm Holding AG
End of Inside Information
27-May-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | info@pentixapharm.com |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2145888 |
| End of Announcement | EQS News Service |
|
|
2145888 27-May-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.